# Risk of adverse COVID-19 outcomes for people living

# with HIV: a rapid review and meta-analysis

Running head: HIV & COVID-19 outcomes: review & meta-analysis

**Authors:** Maya M. MELLOR<sup>1</sup>, Anne C. BAST<sup>1</sup>, Nicholas R. JONES<sup>2</sup>, Nia W. ROBERTS<sup>3</sup>, José M. ORDÓÑEZ-MENA<sup>2,6</sup>, Alastair J.M. REITH<sup>1</sup>, Christopher C. BUTLER<sup>2</sup>, Philippa C. MATTHEWS<sup>4,5</sup>, Jienchi DORWARD<sup>2,7</sup>

#### **Affiliations:**

- 1: Medical Sciences Division, University of Oxford, Oxford, UK
- 2: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
- 3: Outreach Librarian Knowledge Centre, Bodleian Health Care Libraries, Oxford, UK
- 4: Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 5: Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- 6: NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- 7: Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa

Corresponding author: Jienchi Dorward, Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Rd, Oxford OX2 6GG, United Kingdom, jienchi.dorward@phc.ox.ac.uk

It is made available under a CC-BY 4.0 International license .

2

**Requests for reprints:** Jienchi Dorward, Radcliffe Primary Care Building, Nuffield

Department of Primary Care Health Sciences, Radcliffe Observatory Quarter, Woodstock Rd,

Oxford OX2 6GG, United Kingdom, jienchi.dorward@phc.ox.ac.uk

Funding: This work was supported by funding from the Wellcome Trust (216421/Z/19/Z).

Word count: 2498/2500

It is made available under a CC-BY 4.0 International license.

3

**Abstract: (250/250 words)** 

Objective: To assess whether people living with HIV (PLWH) are at increased risk of

COVID-19 mortality or adverse outcomes, and whether antiretroviral therapy (ART)

influences this risk.

**Design**: Rapid review with meta-analysis and narrative synthesis.

Methods: We searched databases including Embase, Medline, medRxiv, and Google Scholar

up to 26<sup>th</sup> August 2020 for studies describing COVID-19 outcomes in PLWH and conducted

a meta-analysis of higher quality studies.

**Results**: We identified 1,908 studies and included 19 in the review. In a meta-analysis of five

studies, PLWH had a higher risk of COVID-19 mortality (hazard ratio (HR) 1.93, 95%

Confidence Interval (CI): 1.59-2.34) compared to people without HIV. Risk of death

remained elevated for PLWH in a subgroup analysis of hospitalised cohorts (HR 1.54, 95%

CI: 1.05-2.24) and studies of PLWH across all settings (HR 2.08, 95%CI: 1.69-2.56). Eight

other studies assessed the association between HIV and COVID-19 outcomes, but provided

inconclusive, lower-quality evidence due to potential confounding and selection bias.

There were insufficient data on the effect of CD4+ T cell count and HIV viral load on

COVID-19 outcomes. Eleven studies reported COVID-19 outcomes by ART-regimen. In the

two largest studies, tenofovir-disoproxil-fumarate (TDF)-based regimens were associated

with a lower risk of adverse COVID-19 outcomes, although these analyses are susceptible to

confounding by comorbidities.

Conclusion: Evidence is emerging that suggests a moderately increased risk of COVID-19

mortality amongst PLWH. Further investigation into the relationship between COVID-19

outcomes and CD4+ T cell count, HIV viral load, ART and the use of TDF is warranted.

**Keywords**: HIV; AIDS; COVID-19; SARS-CoV-2; Antiretroviral therapy

## **Introduction:**

By September 2020, over 30 million people worldwide had been diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1]. Although SARS-CoV-2 infection may be asymptomatic or cause only mild symptoms, a proportion of people develop severe coronavirus disease 2019 (COVID-19), leading to hospitalisation, acute respiratory distress syndrome or death. Established risk factors for severe COVID-19 among the general population include older age, chronic kidney disease and obesity [2].

People living with HIV (PLWH), who constitute approximately 0.5% of the global population [3], may have an increased risk of adverse outcomes from COVID-19 as a result of HIV-associated immune dysfunction [4]. There may also be a higher prevalence of comorbidities amongst PLWH that predispose to unfavourable COVID-19 outcomes [5]. Some antiretroviral agents are under consideration as potential treatments for COVID-19 [6], but the influence of antiretroviral therapy (ART) on COVID-19 outcomes is not known. In this rapid review, we aim to evaluate the evidence regarding the risk of adverse COVID-19 outcomes in PLWH, and the extent to which this risk is modified by other factors including ART.

## **Methods:**

We used rapid review methods to identify studies between 1st January and 26th August 2020 that described COVID-19 outcomes in PLWH and compared outcomes with HIV-negative people or the general population, or that compared outcomes by risk factors amongst PLWH. We searched Embase, Medline, medRxiv, LitCovid, Trip, Google and Google Scholar without language restrictions. Search terms are available in Table S1. One author with extensive literature search expertise performed the initial screen to exclude duplicates and studies not related to HIV. For remaining articles, one author performed title and abstract

screening, with subsequent full text review by two authors using a standardised data extraction form. Disagreements were resolved by a third author. We included pre-prints in order to capture emerging evidence. Studies with ≤15 participants were excluded as they were unlikely to be powered to detect meaningful associations. We critically appraised the quality of studies using checklists for Case Series and for Cohort Studies from the Joanna Briggs Institute [7].

Cohort studies reporting COVID-19-related death in people with and without HIV that adjusted for age, sex and comorbidities were included in a meta-analysis. Cohort-specific relative risks (RRs) and hazard ratios (HRs) were combined with random effects model to account for variability of the true effect between studies. HRs and RRs numerically approximate each other with shorter follow-up, rarer endpoints, and risks closer to 1 [8]. Subgroup analyses were conducted by study setting and method of confounder adjustment. Meta-analysis was performed in R (version 3.6.0) using the *meta* package [9].

# **Results:**

#### **Summary of included studies**

We identified 1,908 records and included 19 studies in our final qualitative analysis (Figure 1). Seventeen studies [10–26] were peer-reviewed and two were preprints [27,28]. Quality appraisal is included in Tables 1, S2 and S3.

We identified five cohort studies (two prospective, three retrospective) comparing COVID-19 related mortality between PLWH and HIV-negative people, which we pooled in a meta-analysis [10,16,18,27,28]. Four of these reported all-cause mortality among people diagnosed with COVID-19 [10,16,18,28] and one reported mortality due to COVID-19 as recorded on death certificates [27]. Of the remaining fourteen studies, seven made multiple comparisons between PLWH with COVID-19 and HIV-negative cohorts, and/or the general population,

and/or PLWH without COVID-19, [11,12,14,15,23,25,26], two studies compared only to a HIV-negative cohort [13,19], two studies compared only cohorts of PLWH with and without COVID-19 [17,22] and three studies compared only the characteristics of PLWH with different COVID-19 disease severity [20,21,24].

There were ten studies that included a total of >1,000 individuals, but amongst these the median number of PLWH with COVID-19 co-infection was only 55 (interquartile range 35-115). Seventeen of the studies were performed in high-income countries and most included a majority of patients on ART with well-controlled HIV (Table 1).

#### Quality of evidence and risk of bias assessment

There were common limitations among the included studies. Most were retrospective analyses of routinely-collected clinical data, meaning identification of COVID-19 cases was not systematic and depended on the local approach to screening and diagnosis. This has varied over time and between settings, and may also differ between PLWH and the general population. Only five studies directly compared COVID-19 outcomes amongst PLWH and HIV-negative people in the same cohort, and accounted adequately for potential confounding by co-morbidities associated with adverse COVID-19 outcomes. Other studies used inadequately matched HIV-negative controls, or the general population, which is susceptible to bias as the exposed and control groups were selected differently. Across all studies, the numbers of PLWH and COVID-19 infection were relatively low.

#### Adjusted analyses of HIV and risk of death in COVID-19:

In a meta-analysis of five cohort studies which accounted for confounding, the risk of death from COVID-19 for PLWH was almost double that of HIV-negative people (HR=1.93, 95% confidence interval [CI] 1.59-2.34) (Figure 1) [10,16,18,27,28]. Three of these studies used large routine databases to identify PLWH across community and hospital settings, in South

Africa [18], the United Kingdom (UK)[27] and United States of America (USA)[10], and two studies were limited to hospitalised PLWH and COVID-19 in the UK [28] and USA [16]. In a subgroup analysis there was no significant difference between study settings (p=0.17), although a weaker HR was seen in hospitalised patients (Figure S1). Among the three studies which used multivariable adjustment to account for confounding [18,27,28], the *crude* risk of COVID-19 death was similar between people with and without HIV, but after adjustment for age, the adjusted risk amongst PLWH was higher. Subsequent adjustment for comorbidities did not drastically alter HRs (Table 1). In sub-group analysis by method of accounting for confounders, a weaker HR was seen in the smaller two studies which used propensity score matching (Figure S2) [10,16].

#### Adjusted analyses of risk of hospitalisation and morbidity in PLWH:

Three of the five cohort studies conducted analyses of the association between HIV status and the risk of other COVID-19 outcomes [10,16,28]. Amongst 47,539 individuals hospitalised with COVID-19 in the UK, the odds of critical care admission was higher among the 115 PLWH (odds ratio (OR) 2.60, 95 % CI 1.74-3.87), but this was attenuated after adjustment for demographics and co-morbidities (aOR 1.13, 95% CI 0.72-1.75) [28]. In the analysis of 50,167 people with COVID-19 in the USA, 404 PLWH (n=404) were at increased risk of hospitalisation compared to 1:1 propensity score matched HIV-negative controls (RR 1.70, 95% CI: 1.21-2.38) [10]. Lastly, among 2,638 people hospitalised with COVID-19 in the USA, there were 6 (28.6%) intensive care unit admissions among 21 PLWH, compared to 7 (16.7%) amongst a propensity score matched cohort of 42 HIV negative people (p = 0.271)[16].

#### Unadjusted analyses of COVID-19 related outcomes in PLWH:

Eight studies provided lower-quality evidence regarding COVID-19 outcomes in PLWH as they did not compare HIV-positive and negative people in the same cohort, or did not adequately account for confounders. The largest of these was a Spanish multi-centre study of 77,590 PLWH, of whom 236 were diagnosed with COVID-19 and 20 died. In keeping with our meta-analysis result, age- and sex-standardised mortality from COVID-19 were found to be higher in PLWH (3.7 per 10,000) compared to the general population (2.1 per 10,000) [11]. The other seven studies [12–15,19,25,26] were limited due to being at single sites, having small sample sizes (median 64, range n=31-161 PLWH diagnosed with COVID-19) and not accounting for potential confounding. These studies report conflicting results with one suggesting a higher rate of hospitalisation and mortality among PLWH compared to the general COVID-19-positive population [12], two studies suggesting lower COVID-19 mortality in PLWH [14,25] and four studies reporting no significant difference in the risk of adverse outcomes from COVID-19 between PLWH and HIV-negative cohorts [13,19] or the general population [15,26].

# Risk of death and hospitalisation in relation to CD4+ T cell count and HIV viral load:

Several of the large cohort studies did not include data on CD4+ T cell count or HIV viral loads [10,27,28]. In the South African study, lower CD4+ T cell counts (measured during the COVID-19 episode) were associated with mortality, but this could be a result of, rather than causing, severe disease (Table 2). There was no difference in outcomes by HIV viral load, although viral load data was incomplete and numbers with unsuppressed viral loads were small [18]. A London HIV clinic found that 18 PLWH who were hospitalised with COVID-19 had a lower median CD4+ T cell count (395 vs 573 cells/μL, p=0.03) compared to their 2,699 PLWH outpatients (Table 2) [17]. A further nine studies (median n= 54 PLWH and

COVID-19, range n=35-93) found no significant association between CD4+ T cell count or HIV viral load and COVID-19 outcomes [13,14,16,20–24,26].

#### **Impact of ART regimen on COVID-19 outcomes:**

No studies compared COVID-19 outcomes between PLWH receiving and not receiving ART. We identified eleven studies assessing the relationship between specific ART regimens and COVID-19 outcomes in PLWH. In South Africa, COVID-19 related mortality was lower in patients on TDF-based regimens versus abacavir/zidovudine-based regimens, which are used for patients with co-morbidities or requiring second line treatment (aHR: 0.42; 95% CI: 0.22-0.78) [18]. While this analysis was adjusted for certain co-morbidities, the observed association may be confounded due to patients receiving TDF having less complex healthcare needs. In the Spanish multi-centre study, PLWH receiving TDF and emtricitabine (FTC) had the lowest risk for COVID-19 diagnosis (16.9 per 10,000) and hospitalisation (10.5 per 10,000) compared to all other ART regimens investigated, but without adjusting for co-morbidities [11]. A US hospital study found that PLWH and COVID-19 who survived were more likely to have been treated with NRTIs that those PLWH who died (99% vs 89%, p=0.04) in univariate analysis [13]. Seven smaller studies (n=18-93 PLWH with COVID-19) reported no significant association between ART-regimen and COVID-19 severity amongst PLWH [14,15,17,20-24].

#### Other factors influencing COVID-19 outcomes among PLWH:

Thirteen studies assessed the influence of comorbidities and demographics on the outcomes of COVID-19 amongst PLWH [13,14,16–18,20–24,26–28]. In the UK-based cohort study of hospitalised patients, among 115 PLWH with COVID-19, the 26 who died were more likely to have obesity and diabetes [28]. Bhaskaran et al and Childs et al report evidence of a higher risk of COVID-19 death and hospitalisation respectively amongst PLWH of black ethnicity

(Bhaskaran et al mortality aHR=3.80; 95% CI: 2.15-6.74, p for interaction=0.045; Childs et al hospitalisation crude OR: 12.22, 95% CI: 1.62-92.00) [17,27]. Other smaller analyses suggested that amongst PLWH, factors such as older age [23], metabolic disorders [23], obesity [14], African ethnicity [23] and organ transplantation [13] were associated with COVID-19 infection or severity.

# **Discussion:**

#### Summary

Emerging evidence suggests an increased risk of COVID-19 related death in PLWH. There was insufficient data to determine whether HIV viral load, CD4+ T cell counts or ART use are associated with COVID-19 related death. We found some evidence that among PLWH receiving ART, TDF use may be associated with lower frequency of SARS-CoV-2 infection and milder courses of COVID-19, although this was not consistent between studies and was susceptible to confounding. Risk factors for severe COVID-19 among PLWH include older age, obesity and black ethnicity, and appear similar to the general population.

#### Risk of COVID-19 related mortality among PLWH

In our review, the two population-based studies from South Africa and the UK both suggested almost double the risk of COVID-19 related death amongst PLWH, despite having very different demographic profiles [18,27]. In contrast, studies restricted to cohorts of PLWH diagnosed with COVID-19 [10], and hospitalised patients with COVID-19 [16,28] found a weaker or null effect. These studies are more at risk of selection bias, as PLWH with milder symptoms may be more likely to test for SARS-CoV-2 or be hospitalised by clinicians (due to a higher perceived risk), compared to people without HIV who may only be tested or hospitalised once more severely unwell. This would lead to the cohort of PLWH being less unwell at baseline compared to the HIV negative cohort, leading to underestimation of any

association between HIV status and COVID-19 related mortality. Furthermore, studies restricted to hospitalised patients cannot account for the effect of HIV (or any other potential risk factor) on SARS-CoV-2 infection and COVID-19 severity which result in hospitalisation, and therefore may underestimate the effect of risk factors on COVID-19 death, compared to studies in the general population [29].

#### **Influence of ART**

We found no evidence to determine whether ART reduces COVID-19 severity through immune reconstitution, as most studies included PLWH on ART. Regarding specific antiretrovirals, the potential therapeutic value of TDF for COVID-19 is supported by results from molecular docking studies [30]. However, TDF is relatively contra-indicated in renal impairment [31], meaning patients receiving TDF-based ART are likely to have less comorbidities, which may explain the observed better COVID-19 outcomes. Randomised trials of TDF prophylaxis for SARS-CoV-2 are underway [32].

#### **Comparisons with existing literature**

PLWH are known to be at higher risk of respiratory bacterial infections, but the evidence regarding acute viral infections is less clear [33]. A review from the H1N1 influenza pandemic in 2009/2010 found some evidence of a higher risk of adverse H1N1 outcomes amongst PLWH who were severely immunocompromised [34]. However, the quality of the evidence was weak with a lack of rigorously-designed prospective cohort studies, reflecting the challenges of in-pandemic research [34].

As of August 26<sup>th</sup> 2020, we identified seven systematic reviews on COVID-19 in PLWH [35–41]. All these reviews lacked the more robust evidence from recent large cohort studies [18,27,28]. Moreover, one review included articles assessing non-HIV related immunodeficiency [38] and four did not address the influence of ART [35,39–41].

#### 12

#### Limitations

Our meta-analysis of five studies is potentially limited by the small numbers of PLWH with COVID-19 who died. This presented challenges when accounting for confounding; studies that used multivariable analyses to adjust for confounding were susceptible to over-fitting of models and potential over-adjustment by factors which could be on the causal pathway between HIV and death (e.g. malignancy or tuberculosis). Studies that used matching were potentially under-powered, which may explain why they tended to report no independent association between HIV and COVID-19 death. In our narrative synthesis, the majority of the studies were small case series or cohort studies that did not adequately account for confounders such as age. Most were performed in high-income countries, and the majority of participants had well-controlled HIV on ART. This may limit the applicability to populations of PLWH in other settings. Only 68% of adults and 53% of children living with HIV globally are receiving ART [42], highlighting a crucial need to examine the risk of COVID-19 complications in these populations.

# **Conclusion:**

We present evidence which suggests a moderately increased risk of COVID-19 death among PLWH. TDF-based ART may be associated with lower risk of COVID-19 diagnosis and adverse outcomes, although this finding is susceptible to confounding. Measures to mitigate COVID-19 risk among PLWH should be included in the global pandemic response, while further research into the role of ART, immunosuppression and viral suppression is needed to quantify and address risks for PLWH in diverse settings.

#### 13

# **Acknowledgements:**

MM, NJ and JD conceived the study. NR performed the literature search. MM and AB contributed equally to the screening and qualitative analysis, with support from NJ and JD. JOM performed the meta-analysis. MM and AB wrote the first draft of the manuscript. MM, AB, NR, JOM, AR, CB, PM, NJ and JD critically reviewed and edited the manuscript and consented to publication.

# **Conflicts of Interest and Source of Funding:**

There are no conflicts of interest to declare. NJ and JD are funded by the Wellcome Trust PhD Programme for Primary Care Clinicians (216421/Z/19/Z).

## **References**

- 1 World Health Organization (WHO). **Weekly Operational Update on COVID-19, 21 August 2020**. 2020; :1–10.
- Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, *et al.* Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw. open. 2020. doi:10.1001/jamanetworkopen.2020.12270
- World Health Organ. HIV/AIDS. 2020.
- Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, Morton CE, et al.
  OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv 2020;
  :2020.05.06.20092999.
- Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective. AIDS Behav Published Online First: 2020. doi:10.1007/s10461-020-02871-9
- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. **Pharmacologic Treatments** for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA J Am Med Assoc* 2020; 323:1824–1836.
- Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al.
  Methodological quality of case series studies. JBI Database Syst Rev Implement
  Reports Published Online First: 2019. doi:10.11124/JBISRIR-D-19-00099
- 8 Symons MJ, Moore DT. **Hazard rate ratio and prospective epidemiological studies**. *J Clin Epidemiol* Published Online First: 2002. doi:10.1016/S0895-4356(02)00443-2

- 9 Schwarzer G. Package "meta" Title General Package for Meta-Analysis. *R News*Published Online First: 2007. doi:10.1007/978-3-319-21416
- Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. Characteristics and outcomes of COVID-19 in patients with HIV: a multi-center research network study. *AIDS*Published Online First: 2020. doi:10.1097/QAD.00000000000002666
- del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, *et al.* Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy.

  Ann Intern Med Published Online First: 2020. doi:10.7326/m20-3689
- Härter G, Spinner CD, Roider J, Bickel M, Krznaric I, Grunwald S, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.
  Infection Published Online First: 2020. doi:10.1007/s15010-020-01438-z
- Sigel K, Swartz T, Golden E, Paranjpe I, Somani S, Richter F, et al. Coronavirus
  2019 and People Living With Human Immunodeficiency Virus: Outcomes for
  Hospitalized Patients in New York City. Clin Infect Dis Published Online First:
  2020. doi:10.1093/cid/ciaa880
- Vizcarra P, Pérez-Elías MJ, Quereda C, Moreno A, Vivancos MJ, Dronda F, et al.
  Description of COVID-19 in HIV-infected individuals: a single-centre,
  prospective cohort. Lancet HIV Published Online First: 2020. doi:10.1016/s2352-3018(20)30164-8
- Shalev N, Scherer M, LaSota ED, Antoniou P, Yin MT, Zucker J, et al. Clinical

  Characteristics and Outcomes in People Living With Human Immunodeficiency

  Virus Hospitalized for Coronavirus Disease 2019. Clin Infect Dis 2020; 24:23–26.
- 16 Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, Rebick G, Klein E, *et al.* Outcomes among HIV-positive patients hospitalized with COVID-19. *J Acquir*

- Immune Defic Syndr Published Online First: 2020. doi:10.1097/QAI.0000000000002423
- 17 Childs K, Post FA, Norcross C, Ottaway Z, Hamlyn E, Quinn K, et al. Hospitalized Patients With COVID-19 and Human Immunodeficiency Virus: A Case Series.

  Clin Infect Dis 2020; :1–2.
- Boulle A, Davies M-A, Hussey H, Ismail M, Morden E, Vundle Z, et al. OUP accepted manuscript. Clin Infect Dis Published Online First: 2020.
  doi:10.1093/cid/ciaa1198
- Miyashita H, Kuno T. Prognosis of coronavirus disease 2019 (COVID-19) in patients with HIV infection in New York City. HIV Med Published Online First: 2020. doi:10.1111/hiv.12920
- 20 Ho H, Peluso MJ, Margus C, Lopes JPM, He C, Gaisa MM, et al. Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV. Infect Dis Soc Am Published Online First: 2020. doi:10.1080/1059924X.2017.1319315
- Di Biagio A, Ricci E, Calza L, Squillace N, Menzaghi B, Rusconi S, *et al.* Factors associated with hospital admission for COVID-19 in HIV patients . *AIDS*Published Online First: 2020. doi:10.1097/QAD.00000000000002663
- Maggiolo F, Zoboli F, Arosio M, Valenti D, Guarneri D, Sangiorgio L, et al.
  SARS□ CoV□2 infection in persons living with HIV: a single center prospective cohort. J Med Virol 2020; :0–2.
- Etienne N, Karmochkine M, Slama L, Pavie J, Batisse D, Usubillaga R, et al. HIV infection and COVID-19. Aids 2020; Publish Ah.
  doi:10.1097/qad.00000000000002651
- Inciarte A, Gonzalez-Cordon A, Rojas J, Torres B, de Lazzari E, de la Mora L, et al.

- Clinical characteristics, risk factors, and incidence of symptomatic COVID-19 in adults living with HIV. *Aids* 2020; Publish Ah. doi:10.1097/qad.000000000000002643
- Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D, et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin Infect Dis Published Online First: 2020. doi:10.1093/cid/ciaa579
- Huang J, Xie N, Hu X, Yan H, Ding J, Liu P, et al. Epidemiological, virological and serological features of COVID-19 cases in people living with HIV in Wuhan City:
  A population-based cohort study. Infect Dis Soc Am Published Online First: June 2020. doi:10.1016/j.euroneuro.2016.03.007
- Bhaskaran K, Ct R, Mackenna B, Schultz A, Mehrkar A, Bates C, et al. HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform (\* Joint principal investigators) Faculty of Epidemiology and Population Health, London Sc. 2020.
- Geretti AM, Stockdale AJ, Kelly SH, Collins S, Waters L, Villa G, et al. Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC 2 WHO Clinical Characterisation Protocol UK Protocol: prospective observational study. 2020.
- 29 Griffith G, Morris TT, Tudball M, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. medRxiv Published Online First: 2020. doi:10.1101/2020.05.04.20090506
- 30 Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Published Online First: 2020. doi:10.1016/j.lfs.2020.117592

- Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med 2018; 19:1–8.
- Polo R, Hernán M. Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS). ClinicalTrials.gov. 2020.https://clinicaltrials.gov/ct2/show/NCT04334928 (accessed 19 Sep2020).
- Benito N, Moreno A, Miro JM, Torres A. Pulmonary infections in HIV-infected patients: An update in the 21st century. *Eur Respir J* 2012; **39**:730–745.
- 34 Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in HIV-infected adults: A review of the literature. Clin Infect Dis 2011; 52:219– 227.
- Baluku JB, Olum R, Agolor C, Nakakande J, Russell L, Bongomin F, et al.

  Prevalence, clinical characteristics and treatment outcomes of HIV and SARSCoV-2 co-infection: a systematic review and meta-analysis. medRxiv 2020;
  :2020.05.31.20118497.
- Masukume G, Mapanga W, Zyl DS van. COVID-19 and HIV co-infection: a living systematic evidence map of current research. medRxiv 2020;
  :2020.06.04.20122606.
- Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. *J Int AIDS Soc* 2020; 23:1–9.
- Gao Y, Chen Y, Liu M, Shi S, Tian J. Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. J Infect 2020; 81:e93–e95.
- 39 Mirzaei H, McFarland W, Karamouzian M, Sharifi H. COVID-19 Among People

- **Living with HIV: A Systematic Review**. *AIDS Behav* Published Online First: 2020. doi:10.1007/s10461-020-02983-2
- 40 Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review. *HIV Med* 2020; :1–11.
- 41 Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, et al.

  AIDS Prevalence of HIV in patients hospitalized for COVID-19 and associated outcomes: a systematic review and meta-analysis-Manuscript Draft-Manuscript Number: Full Title: Prevalence of HIV in patients hospitalized for COVID-19 and associated outcomes: a . medRxiv 2020; :2020.07.03.20143628.
- World Health Organisation. **HIV/AIDS Fact Sheet**.

# **Tables**

Table 1: Details of all included studies with summary of mortality findings and quality appraisal

Study details	Location	Study type and study population	Characteristics of PLWH	Mortality	Quality appraisal*
STUDIES INC	LUDING ALL	COVID-19 PATIENTS (HOSPITALISED AND	IN THE COMMUNITY)		
Boulle et al,	Multi centre:	Prospective cohort study of 540,552 PLWH	34% male, median age 20-39 years. No data on proportions	115 (2.1/10,000) COVID-19 deaths in PLWH vs	JBI C = 11. Risk of confounding by
<b>(2020)</b> [18]	Western Cape	(3978 confirmed COVID-19) & 2,920,380	by ethnicity, ART, or any co-morbidity. 7.6% with VL	510 (1.7/10,000) in adults without HIV.	socio-economic status & BMI.
	, South Africa	HIV-negative adults (18,330 confirmed	>1000 copies/ml or CD $<$ 200 cells/ $\mu L,~34.7\%~with~VL$	Adjusted for age & sex, aHR: 1.97; 95% CI:	
		COVID-19)	unknown in past 15 months.	1.59-2.45. Adjusted for age, sex & co-	
				morbidities: aHR: 2.14; 95% CI: 1.70-2.70 <sup>1</sup> .	socio-economic status & BMI.  JBI C = 11. Small number of
Bhaskaran et	Multi centre,	Retrospective population-based cohort analysis	65% male, median age 40-55 years, 46.2% White, 5.1%	25 (9.1/10,000) COVID-19 deaths in PLWH vs	JBI C = 11. Small number of
al [27],	United	of primary care data of 27,480 PLWH and	Mixed, 4.3% South Asian, 26% Black, 2.3% Other. No data	14,875 (8.6/10,000) in adults without HIV.	outcomes amongst PLWH therefore
(2020)	Kingdom	17,255,425 adults without HIV. Numbers	on proportions with any co-morbidity, or by ART, CD4+	Adjusted for age & sex, aHR: 2.90, 95%	possible overfitting of model.
		diagnosed with COVID-19 not presented.	count, viral suppression	CI:1.96-4.30. Adjsuted for age, sex & co-	
				morbidities, aHR 2.30; 95% CI: 1.55-3.41 <sup>2</sup> .	outcomes amongst PLWH therefore possible overfitting of model.  JBI C = 10. Unclear how COVID-19 diagnosed. 1:1 matching may result in underpowered analysis.
Hadi et al	Multi centre,	Retrospective cohort study amongst people	71% male, mean age 48.1, 50% Black or African American,	20 (4.95%) COVID-19 deaths in PLWH vs 1585	JBI C = 10. Unclear how COVID-19
[10] <b>, 2020</b>	United States	with SARS-CoV-2 infection comparing 404	34% White, 13% Latinx, 3% Asian. No data on proportions	(3.19%, risk ratio [RR] 1.55, 95% CI: 1.01 –	diagnosed. 1:1 matching may result
		PLWH with 49,763 adults without HIV	with any co-morbidity. 70% on ART, no data on CD4 count	2.39) in unmatched cohort, and 15 (3.71%, RR	in underpowered analysis.
		(including matched cohort of 404 adults <sup>3</sup> )	or VL.	1.33, 95% CI: 0.69 – 2.57) in matched cohort.	
del Amo et	Multi centre,	Cohort study of 236 PLWH receiving ART	75% male, median age 50-59 years. 100% receiving ART.	20 (8%) PLWH died, giving age and sex	JBI C = 7. Comparison group from a
al, (2020)	60 Spanish	with COVID-19, recruited from 77,590	No data on ethnicity, CD4 count, viral load or other co-	standardised risk of death of 3.7/10,000 vs	different population. Confounding
[11]	HIV clinics	patients of HIV clinics	morbidities. 64% hospitalised, 6% in ICU.	2.1/10,000 in general Spanish population	factors not accounted for.

					21
Miyashita et	Multi-centre:	Cohort study of people with SARS-CoV-2	78% male, median age 51-65 years. No data on ethnicity,	23 (14%) PLWH died vs 1235 (14%) without	JBI C = 7. Confounding factors not
al [19], 2020	New York,	infection comparing 161 PLWH to 8751	ART, CD4, VL, or proportion with any comorbidity	HIV (but in age <50 years, PLWH had higher	accounted for. Insufficient follow up
	US	people without HIV		risk of death (RR 4.36, 95% CI 1.43-13.3)	time for some patients.
Ho et al [20],	Multi-centre,	Case series of 93 PLWH who presented to ED	72% male, median age 58 years, 40.9% Black, 31.2%	19 (20.4%) PLWH died, no mortality	JBI CS = 8. Deaths amongst those
(2020)	New York,	with positive SARS-CoV-2 RT-PCR test	Hispanic/Latinx. 96% on ART, 84% VL <50 copies/ml,	comparison given	not admitted not recorded.
	US		median CD4 554 cells/μL.		
Di Biagio et	Multi-centre,	Case series of 69 PLWH who were diagnoses	72% male, median age 50-55, 86% Caucasian, 100% on	7 (10.8% of those with known outcomes)	JBI CS = 5. Not clear if participating
al [21], 2020	Italy	with SARS-CoV-2 infection	ART, 88% VL $\!<$ 50 copies/ml, median CD4 580-600	PLWH died, no mortality comparison given	centres identified SARS-CoV-2 cases
			cells/µL.		systematically. Statistics unclear.
					ууа
Maggiolo et	Single-centre,	Cohort study of 55 PLWH with	80% male, median age 54 (IQR: 49-58), 100% receiving	4 (7.2%) PLWH died, no mortality comparison	JBI C = 6. Follow up unclear.
al [22],	Bergamo,	suspected/confirmed COVID-19 vs 69	ART, 98% VL <50 copies/ml, median last CD4 count 904	given	systematically. Statistics unclear.  JBI C = 6. Follow up unclear.  Confounding factors not accounted for. Sample size not large enough for
(2020)	Italy	asymptomatic PLWH who tested negative for	cells/µL, 51% with any co-morbidity.		for. Sample size not large enough for $\frac{0}{0}$
		SARS-CoV-2 (RT-PCR or serology)			multivariable analysis.
					BY
Etienne et al	Single centre,	Case series of <b>54</b> PLWH with symptoms or	61.1% male, median age 54, 100% on ART, 96.2% VL < 40	1 (1.9%) PLWH died, no mortality comparison	JBI CS = 3. COVID-19 case
[23] <b>, (2020)</b>	Paris, France	were hospitalised with COVID-19	copies/mL, median CD4 count 583 cells/mm³, 44.6% Sub	given	multivariable analysis.  JBI CS = 3. COVID-19 case  definition and disease severity not defined. Short follow up time  JBI C = 7. COVID-19 case definition
			Saharan African origin		defined. Short follow up time
					ona
Inciarte et al	Single centre,	Cohort study of 5683 PLWH in of whom 53	85% male, median age 44, median last CD4 cells/mm3 618	2 (4%) PLWH died, no mortality comparison	JBI C = 7. COVID-19 case definition
[24] <b>, (2020)</b>	Barcelona,	PLWH had confirmed or suspected COVID-19	(IQR: 449-834), 96% on ART	given	unclear. Duration of follow-up
	Spain				unclear. Confounding not accounted
					for.
Gervasoni et	Single centre:	Case series of 47 PLWH with	74% male, median age 52 years, no ethnicity data. 100%	2 PLWH died (4.2% of cohort, 15.4% of those	JBI CS = 7. Comparison group from
al, (2020)	Milan, Italy	suspected/confirmed COVID-19	receiving ART, median CD4 count 636 cells/ $\mu L$ , 93.6%	hospitalised with COVID-19) , vs 17% died	a different population. Length of
[25]			with undetectable VL. 64% with $\geq 1$ comorbidity.	among 502 HIV-negative patients admitted with	follow-up unclear. Confounding
				COVID-19 at same hospital	factors not accounted for.

thre, Cohort study 6001 PLWH of voltage diagnosed with COVID-19  thre: Case series of 33 PLWH with the COVID-19  Tes  ONLY HOSPITALISED COVID-19  thre: Prospective cohort study of perhospitalised with suspected/coricord COVID-19. 115 PLWH vs 47,	on ART, median CD4 count 200- 20 copies/mL.  91% male, median age 48 years, receiving ART, overall median C 94% virally suppressed, 60%. wit  PATIENTS  ople 66% male, median age 49-61 year nfirmed (45.3%), Asian (0.9%), Other (12)	1-499 cells/μL, 66% VL < 3869/50333 (7.69%) of gen Wuhan with COVID-19 when with COVID-19 are substituted ar	neral population of different population. Follow-up not clear. Confounding not accounted for.  7% mortality in JBI CS = 7. Comparison group from a different population and confounding not accounted for. Not
covidence of 33 PLWH with the control of the covidence of 33 PLWH with the covidence of 34 PLWH	20 copies/mL.  20 copies/mL.  91% male, median age 48 years, receiving ART, overall median C 94% virally suppressed, 60%. wit  PATIENTS  ople 66% male, median age 49-61 year nfirmed (45.3%), Asian (0.9%), Other (12)	Wuhan with COVID-19  The proof of the proo	clear. Confounding not accounted for.  7% mortality in JBI CS = 7. Comparison group from a different population and confounding not accounted for. Not
only Hospitalised Covid-19  atre: Prospective cohort study of perhospitalised with suspected/cor  COVID-19. 115 PLWH vs 47,	confirmed 91% male, median age 48 years, receiving ART, overall median C 94% virally suppressed, 60%. wit  PATIENTS  ople 66% male, median age 49-61 year nfirmed (45.3%), Asian (0.9%), Other (12)	no ethnicity data. 100% 3 PLWH died (9.1%) vs 3.  CD4 count 670 cells/μL, general COVID19 positive dith ≥1 comorbidity Germany  ars. White (41.5%), Black 26 PLWH died (23%) vs 1.  2.3%). 74% ≥ 1 without HIV. Adjusted for	for.  7% mortality in JBI CS = 7. Comparison group from a different population and confounding not accounted for. Not
only Hospitalised Covid-19  atre: Prospective cohort study of perhospitalised with suspected/cor  COVID-19. 115 PLWH vs 47,	receiving ART, overall median C 94% virally suppressed, 60%. wit  PATIENTS  ople 66% male, median age 49-61 year  nfirmed (45.3%), Asian (0.9%), Other (12)	CD4 count 670 cells/μL, general COVID19 positive ith ≥1 comorbidity Germany  ars. White (41.5%), Black 26 PLWH died (23%) vs 1.  2.3%). 74% ≥ 1 without HIV. Adjusted for	.7% mortality in JBI CS = 7. Comparison group from a different population and confounding not accounted for. Not
only Hospitalised Covid-19  atre: Prospective cohort study of perhospitalised with suspected/cor  COVID-19. 115 PLWH vs 47,	receiving ART, overall median C 94% virally suppressed, 60%. wit  PATIENTS  ople 66% male, median age 49-61 year  nfirmed (45.3%), Asian (0.9%), Other (12)	CD4 count 670 cells/μL, general COVID19 positive ith ≥1 comorbidity Germany  ars. White (41.5%), Black 26 PLWH died (23%) vs 1.  2.3%). 74% ≥ 1 without HIV. Adjusted for	e population in a different population and confounding not accounted for. Not
ONLY HOSPITALISED COVID-19  thre: Prospective cohort study of perhospitalised with suspected/cor  COVID-19. 115 PLWH vs 47,	PATIENTS  ople 66% male, median age 49-61 yearnfirmed (45.3%), Asian (0.9%), Other (12)	ith $\geq 1$ comorbidity Germany  ars. White (41.5%), Black 26 PLWH died (23%) vs 1.  2.3%). 74% $\geq 1$ without HIV. Adjusted for	confounding not accounted for. Not
only Hospitalised Covid-19  atre: Prospective cohort study of perhospitalised with suspected/core  COVID-19. 115 PLWH vs 47,	PATIENTS  ople 66% male, median age 49-61 year  nfirmed (45.3%), Asian (0.9%), Other (12)	ars. White (41.5%), Black 26 PLWH died (23%) vs 1 $(2.3\%)$ . 74% $\geq 1$ without HIV. Adjusted for	all patients with an outcome.  3,955 (29%) in adults   JBI C = 9. 10% with missing   age & sex, aHR:   outcome data.
hospitalised with suspected/co.  COVID-19. 115 PLWH vs 47,	ople 66% male, median age 49-61 yearnfirmed (45.3%), Asian (0.9%), Other (12	2.3%). $74\% \ge 1$ without HIV. Adjusted for	all patients with an outcome.  3,955 (29%) in adults  JBI C = 9. 10% with missing  age & sex, aHR:  outcome data.
hospitalised with suspected/co.  COVID-19. 115 PLWH vs 47,	ople 66% male, median age 49-61 yearnfirmed (45.3%), Asian (0.9%), Other (12	2.3%). $74\% \ge 1$ without HIV. Adjusted for	3,955 (29%) in adults
hospitalised with suspected/coi COVID-19. 115 PLWH vs 47,	nfirmed (45.3%), Asian (0.9%), Other (12	2.3%). $74\% \ge 1$ without HIV. Adjusted for	3,955 (29%) in adults
COVID-19. <b>115</b> PLWH vs 47,		,	age & sex, aHR: outcome data.
,	424 HIV- comorbidity. No data on proportion	: h APT CD4 VI	Adjusted for age sex
		ions by ART, CD4 or VL 1.39; 95% CI: 0.93-2.08. A	rajusted for age, sex
negative adults		and co-morbidities, aHR: 1	1.63; 95% CI: 1.07-
		2.48, p=0.02 <sup>4</sup> .	
ntre: Cohort study of <b>88</b> PLWH hos	spitalised with 78% male, median age 45-67 year	ars. Ethnicity: White (19%), 18 (21%) COVID-19 death	hs in PLWH versus 81 JBI C = 6. Follow up not complete
ls laboratory confirmed COVID-	19 compared to Black, (40%), Hispanic (30%), O	Other (11%). No data on (20%) in adults without HI	IV for all patients. Matched on limited
k, matched cohort of 405 hospital	ised HIV- proportions with any co-morbidit	ty. 100% on ART, 58%	number of confounders. Potential
negative adults <sup>5</sup> .	CD4 >200 cells/μL, 81% VL <50	0 copies/μL	over-adjustment.
ntre: Case series of <b>51</b> PLWH with	84% male mean age 53.3 years, 8	88% white ethnicity. 100% 2 PLWH died (4%) vs 20%	6 amongst general JBI CS = 7. Comparison group from
suspected/confirmed COVID-	receiving ART, median CD4 565	5 cells/μL, 98% virally population admitted to nea	urby hospital with different population. COVID-19 case
	suppressed, 63% with ≥1 comorb	oidity. COVID-19.	definition unclear. Not all cases
a	laboratory confirmed COVID- ork, matched cohort of 405 hospital negative adults <sup>5</sup> .  Case series of <b>51</b> PLWH with	laboratory confirmed COVID-19 compared to  Black, (40%), Hispanic (30%), Cork,  matched cohort of 405 hospitalised HIV-  negative adults <sup>5</sup> .  CD4 >200 cells/µL, 81% VL <5  centre: Case series of 51 PLWH with  suspected/confirmed COVID-19  Black, (40%), Hispanic (30%), Cork,  proportions with any co-morbidi  84% male mean age 53.3 years,  receiving ART, median CD4 565	centre: Cohort study of <b>88</b> PLWH hospitalised with 78% male, median age 45-67 years. Ethnicity: White (19%), 18 (21%) COVID-19 death laboratory confirmed COVID-19 compared to Black, (40%), Hispanic (30%), Other (11%). No data on (20%) in adults without Hispanic adults and the proportions with any co-morbidity. 100% on ART, 58% copies/μL centre: Case series of <b>51</b> PLWH with 84% male mean age 53.3 years, 88% white ethnicity. 100% 2 PLWH died (4%) vs 20% suspected/confirmed COVID-19 receiving ART, median CD4 565 cells/μL, 98% virally population admitted to near

Shalev et al	Single centre:	Case series of 31 PLWH hospitalised for	77% male, mean age 60.7 years, 52% black, 29% Hispanic,	8 PLWH died (27.6%), no mortality comparison	JBI CS = 8. Not all cases completed						
[15], (2020)	New York,	COVID-19 at a large tertiary care medical	9% white. 100% receiving ART, median CD4 396 cells/ $\mu$ L,	given	follow up.						
	US	centre in New York City.	100% virally suppressed, 71% with ≥1 comorbidity								
Karmen-	Multi centre:	Cohort study of <b>21</b> PLWH hospitalised with 90.5% male, mean age 60 years, 24% African American, 6 PLWH died (28.6%) vs 10 (23.8%) in HIV- JCI C = 11.									
Tuohy et al	4 hospitals in	confirmed COVID-19 compared to a matched 38% White, 38% Other. 100% receiving ART, median negative cohort (p=0.682)									
[16] <b>, (2020</b> )	New York, cohort <sup>6</sup> of 42 HIV-negative patients (selected CD4+ 298 cells/μL, 71% VL <50 copies/mL										
	US from 2617 non-HIV patients with COVID-19										
	at same centres)										
O11 11 1											
Childs et al	Single centre:	Case series of 18 PLWH hospitalised with 67% male, median age 52, 94% black ethnicity. 100% on 5 PLWH died (29%), no mortality comparison JCI CS = 6. Time period of the p									
[17] <b>, (2020)</b>	London, UK	confirmed COVID-19. ART, median CD4 395 cells/µL, 94% virally suppressed given enrolment and follow up time									
		defined.									
de											
00			s completed, with comment. See Tables S2 and S3 for full score	S.	<u> </u>						
1. Adjusted for	age, sex, diabetes	s, tuberculosis history and other co-morbidities (hyp	pertension, kidney disease, lung disease)		u u						
Childs et al Single centre: Case series of 18 PLWH hospitalised with 67% male, median age 52, 94% black ethnicity. 100% on 5 PLWH died (29%), no mortality comparison JCI CS = 6. Time period of enrolment and follow up time not defined.  *Joanna Briggs Institute [JBI] Cohort Study [C] or Case Series [CS] checklist items completed, with comment. See Tables S2 and S3 for full scores.  1. Adjusted for age, sex, diabetes, tuberculosis history and other co-morbidities (hypertension, kidney disease, lung disease)  2. Adjusted for age, sex, diabetes, tuberculosis history and other co-morbidities (hypertension, chronic respiratory disease, chronic cardiac disease, diabetes, non-haematological cancer, haematological cancer, chronic liver disease, stroke, dementia, other neurological disease, reduced kidney function, organ transplant, asplenia, rheumatoid arthritis, lupus, psoriasis, or other immunosuppresive disorders)  3. Matched on age, gender, ethnicity, smoking, body mass index, diabetes, hypertension and chronic lung diseases  4. Adjusted for age, sex, ethnicity, baseline date, indeterminate/probable hospital acquisition of COVID-19, ten co-morbidities, and disease severity at presentation  5. Matched on age, gender, body mass index, smoking, co-morbidities (chronic kidney disease, hypertension, asthma, chronic obstructive pulmonary disease, heart failure) and admission date, all from same centre  ART = antiretrovirals, PLWH = people living with HIV, VL = viral load,											
3. Matched on	age, gender, ethni	city, smoking, body mass index, diabetes, hyperten	sion and chronic lung diseases								
4. Adjusted for age, sex, ethnicity, baseline date, indeterminate/probable hospital acquisition of COVID-19, ten co-morbidities, and disease severity at presentation											
5. Matched on	age, sex, race/ethi	nicity and week of SARS-CoV-2 infection			ona						
6. Matched on	6. Matched on age, gender, body mass index, smoking, co-morbidities (chronic kidney disease, hypertension, asthma, chronic obstructive pulmonary disease, heart failure) and admission date, all from same centre										
ART = antiretr	ovirals, PLWH =	people living with HIV, VL = viral load,			S						

<sup>\*</sup> Joanna Briggs Institute [JBI] Cohort Study [C] or Case Series [CS] checklist items completed, with comment. See Tables S2 and S3 for full scores.

- 3. Matched on age, gender, ethnicity, smoking, body mass index, diabetes, hypertension and chronic lung diseases
- 4. Adjusted for age, sex, ethnicity, baseline date, indeterminate/probable hospital acquisition of COVID-19, ten co-morbidities, and disease severity at presentation
- 5. Matched on age, sex, race/ethnicity and week of SARS-CoV-2 infection
- 6. Matched on age, gender, body mass index, smoking, co-morbidities (chronic kidney disease, hypertension, asthma, chronic obstructive pulmonary disease, heart failure) and admission date, all from same centre

<sup>1.</sup> Adjusted for age, sex, diabetes, tuberculosis history and other co-morbidities (hypertension, kidney disease, lung disease)

<sup>2.</sup> Adjusted for age, sex, deprivation, ethnicity, obesity, smoking, and presence of comorbidities (hypertension, chronic respiratory disease, chronic cardiac disease, diabetes, non-haematological cancer, haematological cancer, chronic liver disease, stroke, dementia, other neurological disease, reduced kidney function, organ transplant, asplenia, rheumatoid arthritis, lupus, psoriasis, or other immunosuppresive disorders)

Table 2: Summary of studies reporting outcomes by ART regimen and other risk factors for adverse COVID-19 outcomes amongst people living with HIV

STUDY	INFLUENCE OF ART REGIMENS	OTHER RISK FACTORS AMONG PLWH
Boulle et al, (2020)	Lower mortality in patients on TDF vs	601 patients had CD4 count measured during episode of C-
[18] <b>n=3978</b>	abacavir/zidovudine (aHR: 0.42; 95%	19. Higher mortality associated with CD4 counts <200
	CI: 0.22;0.78)	cells/µL (n=70) vs ≥350 cells/µl (aHR 1.97; 95% CI 1.14-
		3.40). Direction of causality unclear.
		No difference in hazard of C-19 death by HIV VL (aHR vs
		HIV-negative: 2.61 (95% CI: 1.98-3.43) for VL < 1000
		copies/mL; 3.35 (95% CI: 1.38-6.12) for VL ≥ 1000
		copies/mL or CD4 <200 cells/µl).
Bhaskaran et al [27], (2020)	N/A	PLWH of Black ethnicity had higher risk of COVID-19
Number of PLWH &		mortality (aHR 3.80, p for interaction 0.045). No data on
COVID-19 not presented		outcomes by CD4 or VL.
del Amo et al, (2020) [11]	Lowest risk for C-19 diagnosis (16.9%	Higher crude risk of C-19 death amongst older PLWH (70-
n=236	[95% CI: 10.5 - 25.9) & hospitalisation	79 years = 26.6/10,000, 95% [CI 10.7–54.9] vs 50-59 years
	(10.5 [95% CI: 5.6 - 17.9] ) in PLWH	2.2/10,000 [95% CI 10.7-54.9]). No difference by sex.
	receiving TDF/FTC compared to other	
	ART regimens (e.g. ABC/3TC 28.3%	
	[95% CI: 21.5 - 36.7] and 23.4% [95%	
	CI: 17.2 - 31.1] respectively).	
Ho et al [20], (2020)	No significant difference in TDF use	No significant differences in obesity, CD4 counts or HIV
n=93	between PLWH with C-19 who survived	VL between PLWH with C-19 who survived and died
	and died (73.6% vs 55.5%, p=0.15).	
Di Biagio et al [21], 2020	No stat. sig. association between risk of	Hospitalised PLWH were slightly older (p=0.047). No
n=69	hospitalisation and ART regimens	association between most recent VL or CD4 count and
		hospitalisation.
Maggiolo et al [22], (2020)	No difference in TDF use amongst	4 PLWH with C-19 who died had lower last CD4 count
n=55	PLWH with C-19 (60%) vs without C-	(median 514 cells/ $\mu L$ ) than the 51 PLWH who survived
	19 (60.8%)	(median 913 cells/ $\mu$ L).
Etienne et al [23], (2020)	No stat. sig. difference between ART	No stat. sig. association between CD4 counts or $VL < 40$
n=54	regimen and C-19 severity	copies/ml and C-19 severity
Inciarte et al [24], (2020)	No associations between ART regimen	No association between latest CD4 count and C-19 severity
n=53	and C-19 severity	
Huang et al [26], 2020	N/A	Older age and ART discontinuation associated with C-19
n=35		infection. No association between latest CD4 count or VL
		and C-19 infection.

Geretti et al [28], (2020)	N/A	Age, obesity and diabetes were associated with C-19 death
n=115		amongst PLWH.
Sigel et al [13], (2020)	PLWH who survived were more likely	No association between comorbidities, latest CD4 count or
n=88	to have been treated with NRTIs than	VL and C-19 death.
	those PLWH who died (99% v 89%,	
	p=0.04) in univariate analysis. No	
	difference in outcomes for other classes	
	of ART.	
Vizcarra et al, [14], (2020)	Increased TAF use in PLWH with C-19	PLWH with C-19 were significantly more likely to have
n=51	(37/51, 73%), vs PLWH without	comorbidities (63% vs 38%, P=0.00059), and had higher
	COVID-19 (38%, p=0·0036)	median BMI (25.5 kg/m $^2$ vs 23.7 kg/m $^2$ , P=0.021) compared
		to 1288 PLWH without C-19. No association between
		CD4+ T cell count and SARS-CoV-2 infection or adverse
		C-19 outcomes.
Shalev et al [15], (2020)	7/8 (88%) PLWH who died from	N/A
n=31	C-19 used TAF/TDF vs 10/23 (43%) of	
	those who survived	
Karmen-Tuohy et al [16],	N/A	No association between most recent CD4 count and
(2020)		mortality (OR 0.996, 95% CI: 0.992 to 1.11)
n=21		
Childs et al [17], (2020)	More common use of protease inhibitor-	PLWH hospitalised with C-19 were more likely to be of
n=18	containing ART regimens among	black ethnicity (OR: 12.22, 95% CI: 1.62-92.00), and had
	PLWH with C-19 (OR, 2.43, 95% CI,	lower median CD4+ cell counts (395 vs 573, P=0.03)
	.94–6.29)	

3TC = lamivudine, ABC = abacavir, FTC = emtricitabine, ART = antiretroviral therapy,

BMI = body mass index, C-19 = COVID-19, OR = odds ratio, PLWH = people living with

HIV, stat. sig. = statistically significant, TAF = tenofovir alafenamide, TDF = tenofovir

disoproxil fumarate, VL = viral load

It is made available under a CC-BY 4.0 International license.

26


**Figures** 

Figure 1: PRISMA Flow diagram to show studies identified and included in a systematic meta-analysis of outcomes of COVID-19 in people living with HIV (PLWH)

#### Figure 2 Meta-analysis of the effect of HIV on risk of COVID-19 death.

Figure 2 caption: Country; UK = United Kingdom, US = United States of America, ZA = South Africa. HIV+ and HIV- refers to people with and without HIV. C19 refers to those with COVID-19. The denominators (N) refer to the original population where reported: A cohort of people diagnosed with HIV and the wider general population without HIV. Not all studies reported this information. Results are reported as hazard ratios (HR) with 95% confidence intervals (95%CI).

It is made available under a CC-BY 4.0 International license.



			HIV+			HIV-						
Study	Country	N	C19	Death	N	C19	Death	Haz	zard Ratio	HR	95%-CI	Weight
Boulle	ZA	540552	3978	115	2920380	18330	510		-	2.14 (1	.70 to 2.70)	47.8%
Bhaskaran	UK	27480	n/a	25	17255425	n/a	14857			- 2.30 (1	.55 to 3.42)	20.6%
Hadi	US	n/a	404	20	n/a	404	15		-	1.33 (0	.69 to 2.57)	8.2%
Geretti	UK	n/a	115	26	n/a	47424	13955			1.63 (1	.07 to 2.48)	18.6%
Karmen-Tuohy	US	n/a	21	6	n/a	42	10	-	-	1.20 (0	.50 to 2.85)	4.8%
Random effects model Heterogeneity: $I^2 = 11\%$ , $\tau^2 = 0.0065$ , $p = 0.34$							_		<b>\rightarrow</b>	1.93 (1.	.59 to 2.34)	100.0%
Heterogeneity: $I^2 = 11\%$ ,	$\tau^2 = 0.0065$	p = 0.34					0.0	0.5	1 0	Ė		
							0.2	0.5	1 2	5		